NasdaqGS - Nasdaq Real Time Price USD

Legend Biotech Corporation (LEGN)

43.24

-2.28

(-5.01%)

At close: May 10 at 4:00 PM EDT

45.76

+2.52

(+5.83%)

Pre-Market: 8:58 AM EDT

Legend Biotech Reports First Quarter 2024 Results and Recent Highlights

SOMERSET, N.J., May 13, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2024 unaudited financial results and key corporate highlights.

Business Wire 2 hours ago

LEGN
-5.01%
Should You Buy Legend Biotech (LEGN) Ahead of Earnings?

Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks 4 days ago

LEGN
-5.01%
$CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma$
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

SOMERSET, N.J., April 22, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that the European Commission (EC) has granted approval of CARVYKTI® (ciltacabtagene autoleucel, cilta-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), have demonstrated disease progression on

Business Wire 20 days ago

LEGN
-5.01%
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results

SOMERSET, N.J., April 11, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, May 13, 2024, to review first-quarter 2024 results.

Business Wire last month

LEGN
-5.01%
FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma

Following the label expansion, J&J's (JNJ) Carvykti is approved as a second-line treatment for adults with relapsed/refractory myeloma. It was initially approved for use as a fifth- or later-line treatment.

Zacks last month

JNJ

LEGN
-5.01%
CELG-RT
Why Legend Biotech (LEGN) Stock Might be a Great Pick

Legend Biotech (LEGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks last month

LEGN
-5.01%
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma

SOMERSET, N.J., April 06, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI), and an immunomodulatory agent (IMiD), and are refractory to lenalidomide.1 CARVYKTI®

Business Wire last month

LEGN
-5.01%
Should You Continue to Hold Legend Biotech Corporation (LEGN)?

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Contrarian Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. Optimism started to prevail, during the last months of the year, and investors reacted positively to news of a potential change in direction by the US Federal Reserve, as well as […]

Insider Monkey last month

LEGN
-5.01%
Management’s Conservative Guidance Led Legend Biotech Corporation (LEGN) to Decline in Q4

TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the fourth quarter, the strategy underperformed the Russell Midcap Growth Index and returned 13.66% (gross) and 13.44% (net) while the index return was -14.55%. In addition, please check […]

Insider Monkey last month

LEGN
-5.01%
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report

SOMERSET, N.J., March 19, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today released its inaugural Environmental, Social & Governance (ESG) report. The inaugural report provides an overview of Legend Biotech’s ESG program and reporting in alignment with the Sustainable Accounting Standards Board ("SASB") Biotechnology and Pharmaceutical sector standards, the Company’s ESG data collection and disclosure roadmap, and future growth areas in its

Business Wire last month

LEGN
-5.01%
30 Biggest Biotechnology Companies in the World

In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]

Insider Monkey last month

ILMN

AZN

EXEL
$CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma$
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma

SOMERSET, N.J., March 15, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended CARVYKTI® (ciltacabtagene autoleucel, cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD

Business Wire last month

LEGN
-5.01%
Legend Biotech Corporation (NASDAQ:LEGN) Q4 2023 Earnings Call Transcript

Legend Biotech Corporation (NASDAQ:LEGN) Q4 2023 Earnings Call Transcript March 11, 2024 Legend Biotech Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to Legend Biotech Reports Fourth Quarter Earnings Call. At this time, all participants […]

Insider Monkey 2 months ago

LEGN
-5.01%
JNJ
The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys

Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys are part of the Zacks top Analyst Blog.

Zacks 2 months ago

EXEL

MOR.DE

LEGN
-5.01%
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights

SOMERSET, N.J., March 11, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its fourth quarter and full year 2023 unaudited financial results and key corporate highlights.

Business Wire 2 months ago

LEGN
-5.01%
5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024

We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.

Zacks 2 months ago

LEGN
-5.01%
EXAS

MOR.DE
An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 47% Undervalued

Key Insights Using the 2 Stage Free Cash Flow to Equity, Legend Biotech fair value estimate is US$124 Current share...

Simply Wall St. 2 months ago

LEGN
-5.01%
$Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy$
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy

SOMERSET, N.J., February 23, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended expansion of the CARVYKTI® label to include adult patients with relapsed and refractory multiple myeloma, who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor, have demonstrated disease p

Business Wire 2 months ago

LEGN
-5.01%
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results

SOMERSET, N.J., February 13, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, will host a conference call for investors at 8:00 am ET on Monday, March 11, 2024, to review fourth-quarter and full-year 2023 results.

Business Wire 2 months ago

LEGN
-5.01%
Matthews Emerging Markets Small Companies Fund Bolsters Position in CarTrade Tech Ltd

Insightful 13F Filing Update Reveals Strategic Portfolio Adjustments

GuruFocus.com 3 months ago

LEGN
-5.01%

Performance Overview

Return	LEGN	MSCI WORLD
YTD	-28.14%	+7.96%
1-Year	-38.46%	+21.79%
3-Year	+42.47%	+18.93%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Legend Biotech Corporation (LEGN)

Legend Biotech Reports First Quarter 2024 Results and Recent Highlights

Should You Buy Legend Biotech (LEGN) Ahead of Earnings?

CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results

FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma

Why Legend Biotech (LEGN) Stock Might be a Great Pick

Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma

Should You Continue to Hold Legend Biotech Corporation (LEGN)?

Management’s Conservative Guidance Led Legend Biotech Corporation (LEGN) to Decline in Q4

Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report

30 Biggest Biotechnology Companies in the World

CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Legend Biotech Corporation (NASDAQ:LEGN) Q4 2023 Earnings Call Transcript

The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys

Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights

5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024

An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 47% Undervalued

Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results

Matthews Emerging Markets Small Companies Fund Bolsters Position in CarTrade Tech Ltd

Performance Overview